Posted by Michael Wonder on 20 Nov 2020
FDA authorises drug combination for treatment of COVID-19
19 November 2020 - Today, the U.S. FDA issued an emergency use authorisation for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and paediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
In a clinical trial of hospitalised patients with COVID-19, baricitinib, in combination with remdesivir, was shown to reduce time to recovery within 29 days after initiating treatment compared to patients who received a placebo with remdesivir.
